1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Brain Diseases in 18 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 9 (50.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Langston, JW | 1 |
| Forno, LS | 1 |
| Rebert, CS | 1 |
| Irwin, I | 1 |
| Bernocchi, G | 1 |
| Gerzeli, G | 1 |
| Scherini, E | 1 |
| Vignola, C | 1 |
| Sziráki, I | 1 |
| Kardos, V | 1 |
| Patthy, M | 1 |
| Pátfalusi, M | 1 |
| Budai, G | 1 |
| Schapira, AH | 1 |
| Morissette, M | 1 |
| Goulet, M | 1 |
| Calon, F | 1 |
| Falardeau, P | 1 |
| Blanchet, PJ | 1 |
| Bédard, PJ | 1 |
| Di Paolo, T | 1 |
| Lan, J | 1 |
| Jiang, DH | 1 |
| Klivenyi, P | 1 |
| St Clair, D | 1 |
| Wermer, M | 1 |
| Yen, HC | 1 |
| Oberley, T | 1 |
| Yang, L | 1 |
| Flint Beal, M | 1 |
| Villares, J | 1 |
| Faucheux, B | 1 |
| Herrero, MT | 1 |
| Obeso, JA | 1 |
| Duyckaerts, C | 1 |
| Hauw, JJ | 1 |
| Agid, Y | 1 |
| Hirsch, EC | 1 |
| Wu, WR | 1 |
| Zhu, XZ | 1 |
| Kay, JN | 1 |
| Blum, M | 1 |
| Pennypacker, KR | 1 |
| Yang, X | 1 |
| Gordon, MN | 1 |
| Benkovic, S | 1 |
| Miller, D | 1 |
| O'Callaghan, JP | 1 |
| Dryhurst, G | 1 |
| Quik, M | 1 |
| Polonskaya, Y | 1 |
| McIntosh, JM | 1 |
| Kulak, JM | 1 |
| Hu, SC | 1 |
| Chang, FW | 1 |
| Sung, YJ | 1 |
| Hsu, WM | 1 |
| Lee, EH | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Testa, B | 1 |
| Jenner, PG | 1 |
| Marsden, CD | 2 |
| Naylor, RJ | 1 |
| Schneider, JS | 1 |
| Markham, CH | 1 |
| Sundström, E | 1 |
| Strömberg, I | 1 |
| Tsutsumi, T | 1 |
| Olson, L | 1 |
| Jonsson, G | 1 |
| Jenner, P | 1 |
| Boyce, S | 1 |
4 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Brain Diseases
| Article | Year |
|---|---|
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease | 1997 |
Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; Dopamine; Dopamine Uptake Inh | 2001 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocripti | 1988 |
14 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Brain Diseases
| Article | Year |
|---|---|
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Diseases; Disease | 1984 |
Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Axons; Brain Diseases; Dihydroergotoxine; Dop | 1993 |
Methamphetamine protects against MPTP neurotoxicity in C57BL mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amphetamine; Animals; Bra | 1994 |
Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Autoradiography; Behavi | 1996 |
Manganese superoxide dismutase overexpression attenuates MPTP toxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1998 |
[125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Brain | 1998 |
Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo biloba extract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; Corpus Striatum; Dopamine; Fe | 1999 |
Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Diseases; Cell Differentiat | 2000 |
Long-term induction of Fos-related antigen-2 after methamphetamine-, methylenedioxymethamphetamine-, 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine- and trimethyltin-induced brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; DNA-Binding Proteins; Dopamin | 2000 |
Differential nicotinic receptor expression in monkey basal ganglia: effects of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkaloids; Animals; Azocines; Basal Ganglia; Brain Dis | 2002 |
Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Biogenic Monoamines; Brain; | 1991 |
The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 1985 |
Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Diseases; Cats; Cell Survival; Immunoen | 1986 |
Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Fibers; Animals; Brain; Brain Diseases; Cat | 1987 |